Guidance for payers related to unreasonable documentation for immunotherapy
Read our easy-to-use summary sheet of guidance for payers re reasonable and unreasonable requests for 95165 documentation.
FDA proposes phenylephrine removal from oral OTC drugs
Only a final order will affect which products may be marketed. The proposed order is based on effectiveness concerns, not on safety concerns.
We’ve come a long way
This year, much of our advocacy effort has been devoted to influencing changes to the 2025 Proposed Medicare Physician Fee Schedule.
ACAAI in the News
Here are the recent national media hits for the American College of Allergy, Asthma & Immunology.
Register now for the 2024 Financial Update for Allergists webinar, Weds., Dec. 4 at 7:00 pm CT
Get the latest allergist compensation and E&M coding data. Plus, find revenue-generating opportunities and ways to use artificial intelligence that make fi…
New guidance for payers related to unreasonable documentation for immunotherapy
The recommendations lay out what the authors see as reasonable and unreasonable requests for documentation for allergy immunotherapy services.
November issue of Annals focuses on COVID-19 and its long-term effects
The November issue of Annals of Allergy, Asthma & Immunology is focused on COVID-19 and its long-term effects.
Latest Issue of AllergyWatch: November-December 2024
in AllergyWatchA Synopsis of Allergy and Asthma Literature, Resulting from an Unbiased,Comprehensive Review of Twenty Major Medical Journals.
ACAAI Member Webinars – Register now!
Upcoming webinars include The Asthma Urgency Shifting the Rescue Paradigm, How To Use Genetic Testing in Your Office, and more!
New guidance for payers related to unreasonable documentation for immunotherapy
The recommendations lay out what the authors see as reasonable and unreasonable requests for documentation for allergy immunotherapy services.
… results.
